Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 75

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 75
---
 connection with the Transaction based on Leerink Partners’
longstanding relationship and familiarity with Repare and its business, as well as its

42

experience and expertise in the pharmaceutical industry. Leerink Partners is an internationally recognized investment banking firm that has substantial experience in transactions similar to the
Transaction.

In connection with Leerink Partners’ services as a financial advisor to Repare, Repare has agreed to pay Leerink
Partners an aggregate fee of $4 million, of which opinion fees of $1 million have been paid and the remainder of which is payable contingent upon consummation of the Transaction. In addition, Repare has agreed to reimburse certain of
Leerink Partners’ expenses arising related to the Transaction, and to indemnify Leerink Partners against certain liabilities, including liabilities under federal securities laws, that may arise, out of Leerink Partners’ engagement. The
terms of the fee arrangement between Leerink Partners and Repare, which are customary in transactions of this nature, were negotiated at arm’s length between Leerink Partners and Repare, and the Repare Board was aware of the arrangement,
including the fact that a significant portion of the fee payable to Leerink Partners is contingent upon the completion of the Transaction.

Plans for the Company After the Arrangement

The primary purposes of the Arrangement are to facilitate the Discontinuance and to provide
Shareholders with cash sooner than would be the case in the context of a statutory liquidation, while retaining $4,000,000 of the Company’s Closing Net Cash as a transaction fee. Upon completion of the Arrangement, the Purchaser expects the
Company to have sufficient funds to cover anticipated expenses through dissolution of the Company. Following the Arrangement, the Common Shares will be delisted from Nasdaq, in accordance with applicable laws, rules and regulations, and will apply
to cease to be a reporting issuer in Québec under applicable Canadian Securities Laws, thereby reducing the administrative and financial burdens (and associated costs) associated with remaining a reporting issuer. The Common Shares will be
deregistered under the Exchange Act. Following the completion of the Arrangement and such deregistration, the Company will no longer file period reports with the SEC.

Certain Effects of the Arrangement

Following the consummation of the Arrangement, the registration of the Common Shares under the Exchange Act will be terminated. Due to this
termination, the Company will no longer be required to file annual, quarterly and current reports with the SEC. Moreover, the Company will no longer be subject